Mángwelé ma Epatíte A ezalí mángwelé oyo ebatelaka batu na epatíte A.[1] Eza na nguya ya kosala kino na 95% ya ba cas mpe esalaka au moins mibu zomi na mitano mpe ntango mususu na bomoyi mobimba ya mutu.[1][2] Soki epesami, esengelaka ete ezala dose mibale kobanda nasima ya mobu moko ya mbotama. Epesamaka na tonga na musunyi ya nzoto.[1]

Organisation Mondiale ya Santé (OMS) esengaka ete mángwelé epesama na batu nionso na bisika biye bokono bozwi batu mua mingi. Bisika biye bokono bozwi batu mingi mpeza, esengelaka te kopesa mángwelé bisika binso mpo ete mingi mpeza bokengi ya nzoto ya batu ezalaka esi elendisami na nzela ya infection bazwaki ntango bazalaki bana.[1]  Center for Disease Control and Prevention (CDC) esengaka ete bapesa mángwelé na batu bakolo oyo bazali na risque monene mpe na bana banso.[3]

Ba effet secondaire ya makasi ezalaka mpeza te. Mpasi na esika babetaki tonga esalaka pene na 15% ya bana mpe ndambu ya batu bakolo. Mángwelé mingi ya epatíte A ezalaka na virus oyo eza activé te mpe mua misusu ezalaka na virus oyo balembisi. Oyo ezalaka na virus oyo balembisi ezalaka recommandé te na eleko ya zemi to mpo na baye baza na bokengi ya nzoto eye ekosala malamu te. Mua ba formule ezalaka bosangisi ya mángwelé epatíte A na oyo ya epatíte B to mángwelé ma typhoide.[1]

Mángwelé ya yambo ya epatíte A endimamaki na Eropa na mobu ya 1991 mpe na Etats Unis na mobu ya 1995..[4] Mángwelé oyo ezali na Liste ya ba Nkisi ya Ntina ya Organisation Mondiale ya Santé, nkisi ya ntina mpeza oyo esengeli kozanga te na ba lopitalo.[5] Na Etats Unis talo nayango ezalaka kati ya 50 na 100 USD.[6]

References kokoma

  1. 1,0 1,1 1,2 1,3 et 1,4 "WHO position paper on hepatitis A vaccines – June 2012.". Wkly Epidemiol Rec 87 (28/29): 261–76. Jul 13, 2012. PMID 22905367. http://www.who.int/wer/2012/wer8728_29.pdf. 
  2. Ott JJ, Irving G, Wiersma ST (December 2012). "Long-term protective effects of hepatitis A vaccines. A systematic review". Vaccine 31 (1): 3–11. doi:10.1016/j.vaccine.2012.04.104. PMID 22609026. 
  3. "Hepatitis A In-Short". July 25, 2014. http://www.cdc.gov/vaccines/vpd-vac/hepa/in-short-adult.htm#who. Retrieved 7 December 2015. 
  4. (en) Vandana Patravale, Prajakta Dandekarmpé Ratnesh Jain, Nanoparticulate drug delivery perspectives on the transition from laboratory to market, Oxford, 1. publ.,‎ 2012 (ISBN 9781908818195, lire en ligne), p. 212
  5. "19th WHO Model List of Essential Medicines (April 2015)". WHO. April 2015. http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf. Retrieved May 10, 2015. 
  6. (en) Richart Hamilton, Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition, Jones & Bartlett Learning,‎ 2015 (ISBN 9781284057560), p. 314